Endocrine Flashcards
Drug class for Levothyroxine
thyroid agent (T4)
MoA for Levothyroxine
replacement T4 converted to T3 in peripheral tissues -> nuclear receptors -> protein synthesis, metabolic rate, promotes gluconeogenesis
Indications for Levothyroxine
hypothyroidism, thyroid cancer
Drug class for Liothyronine
thyroid agent (T3)
MoA for Liothyronine
T3 in peripheral tissues -> nuclear receptors -> protein synthesis, metabolic rate, promotes gluconeogenesis
Indications for Liothyronine
hypothyroidism not responsive to T4 therapy; tx of myxedema coma
Drug class for Radioactive Iodine
antithyroid agent
MoA for Radioactive Iodine
radioactive iodine is concentrated in thyroid gland w/ death of gland cells over 6-8 weeks
Indications for Radioactive Iodine
thyroid ablation without surgery
Drug class for Methimazole
antithyroid agents
MoA for Methimazole
blocks oxidation of iodine in thyroid gland preventing iodine combining w/ tyroisin to form T4, T3; doesn’t inactivate circulating T4, T3
Indications for Methimazole
hyperthyroidism
Drug class for Prophylthiouracil [PTU]
anti-thyroid drug
thiamine
MoA for Prophylthiouracil [PTU]
interfere w/ thyroid hormone synthesis; inhibits conversion of T4 to T3; has immunosuppressive effects (bone marrow)
Indications for Prophylthiouracil [PTU]
Graves disease, pre-thyroid surgery or RAI131 therapy, thyrotoxic crisis
Drug class for Prednisone
glucocorticoids
Drug class for Prednisolone
glucocorticoids intermediate acting
Drug class for Dexamethasone
glucocorticoids long acting
MoA for Prednisone, Prednisolone, Dexamethasone
suppresses adrenal function at high dose; dec leukocyte migration; enters cell nucleus to alter synthesis of protein
Indications for Prednisone, Prednisolone, Dexamethasone
multiple; immunosuppressive functions
Drug class for Fludrocortisone
mineralcorticoids
MoA for Fludrocortisone
promotes increased distal renal tubule absorption of Na+ and loss of K+
Indications for Fludrocortisone
Addison’s disease (adrenocortical insufficiency); resistant orthostatic hypotension
Drug class for Propanolol
adjunct drugs: nonselective beta blocker
MoA for Propanolol
adrenergic B1 & B2 receptor inhibitor; reduction in myocardial oxygen demand
Indications for Propanolol
angina, HTN, tachycarrhythmias, essential tremor, migraine Pa, anxiety
Drug class for Metoprolol
adjunct drugs: selective beta blockers (B1)
MoA for Metoprolol
selective B1 adrenergic receptor inhibitor
Indications for Metoprolol
angina, HTN, hemodynamically stable MI
Drug class for Raloxifine
selective estrogen receptor modulators (SERMs)
MoA for Raloxifine
binds to selected estrogen receptors & dec bone resorption
Indications for Raloxifine
px/tx osteoporosis
Drug class for Alendronate
bisphosphenate: oral
MoA for Alendronate
decrease rate of bone resorption
Indications for Alendronate
px/tx of osteoporosis in women; tx in men; Paget’s disease
Drug class for Zoledronic Acid
bisphosphenate: IV
MoA for Zoledronic Acid
inhibits osteoclast activity & skeletal calcium release
Indications for Zoledronic Acid
px/tx osteoporosis; tx multiple myeloma, metastatic bone lesions, hypercalcemia of malignancy, Paget’s disease
Drug class for Calcitonin Salmon
calcitonin
MoA for Calcitonin Salmon
protein sequence similar to human calcitonin; antagonizes impact of parathyroid hormone & inhibits osteoclast activity
Indications for Calcitonin Salmon
osteoporosis, Paget’s disease, hypercalcemia
Drug class for Teriparatide
recombinant human parathyroid hormone
MoA for Teriparatide
recombinant form PTH (1-34); stimulates new bone formation
Indications for Teriparatide
tx severe/tx-resistant osteoporosis (max 2 yrs use)